Takeda Pharmaceutical Company Limited (NYSE:TAK) went down by -1.02% from its latest closing price compared to the recent 1-year high of $19.97. The company’s stock price has collected -2.85% of loss in the last five trading sessions. Press Release reported on 11/23/21 that Takeda’s LIVTENCITY(TM) (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
Is It Worth Investing in Takeda Pharmaceutical Company Limited (NYSE :TAK) Right Now?
Takeda Pharmaceutical Company Limited (NYSE:TAK) scored a price-to-earnings ratio above its average ratio, recording 10.39 x from its present earnings ratio. Plus, the 36-month beta value for TAK is at 0.97. Opinions of the stock are interesting as 7 analysts out of 14 who provided ratings for Takeda Pharmaceutical Company Limited declared the stock was a “buy,” while 1 rated the stock as “overweight,” 6 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $18.97, which is $5.22 above the current price. TAK currently public float of 3.13B and currently shorts hold a 0.30% ratio of that float. Today, the average trading volume of TAK was 2.32M shares.
TAK’s Market Performance
TAK stocks went down by -2.85% for the week, with a monthly drop of -1.52% and a quarterly performance of -18.26%, while its annual performance rate touched -22.49%. The volatility ratio for the week stands at 0.84% while the volatility levels for the past 30 days are set at 1.18% for Takeda Pharmaceutical Company Limited. The simple moving average for the period of the last 20 days is -3.63% for TAK stocks with a simple moving average of -17.92% for the last 200 days.
Analysts’ Opinion of TAK
Cowen gave a rating of “Market Perform” to TAK, setting the target price at $19.50 in the report published on November 01st of the previous year.
TAK Trading at -8.60% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.63% of loss for the given period.
Volatility was left at 1.18%, however, over the last 30 days, the volatility rate increased by 0.84%, as shares sank -1.23% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.71% lower at present.
During the last 5 trading sessions, TAK fell by -2.85%, which changed the moving average for the period of 200-days by -22.13% in comparison to the 20-day moving average, which settled at $14.16. In addition, Takeda Pharmaceutical Company Limited saw -25.00% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- +14.00 for the present operating margin
- +56.24 for the gross margin
The net margin for Takeda Pharmaceutical Company Limited stands at +11.76. The total capital return value is set at 4.38, while invested capital returns managed to touch 3.81. Equity return is now at value 9.30, with 3.80 for asset returns.
Based on Takeda Pharmaceutical Company Limited (TAK), the company’s capital structure generated 98.12 points at debt to equity in total, while total debt to capital is 49.53. Total debt to assets is 39.28, with long-term debt to equity ratio resting at 96.72. Finally, the long-term debt to capital ratio is 48.82.
When we switch over and look at the enterprise to sales, we see a ratio of 2.67, with the company’s debt to enterprise value settled at 0.49. The receivables turnover for the company is 4.00 and the total asset turnover is 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.53.